|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.30 | 89.11 | 103.69 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
132.40
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 973.36 | 815.56 | 874.68 | 911.07 | Total Expenditure | 903.60 | 793.63 | 909.42 | 908.65 | PBIDT (Excl OI) | 69.76 | 21.93 | -34.74 | 2.42 | Other Income | 0.02 | 0.29 | 0.20 | 2.92 | Operating Profit | 69.78 | 22.22 | -34.54 | 5.35 | Interest | 33.10 | 32.45 | 34.12 | 34.34 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 36.68 | -10.23 | -68.66 | -28.99 | Depreciation | 36.24 | 37.30 | 34.19 | 27.50 | Profit Before Tax | 0.44 | -47.53 | -102.85 | -56.49 | Tax | -4.56 | -11.94 | -7.50 | -12.63 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 5.00 | -35.59 | -95.35 | -43.86 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 5.00 | -35.59 | -95.35 | -43.86 | Equity Capital | 158.28 | 158.28 | 158.28 | 158.28 | Face Value (IN RS) | 10 | 10 | 10 | 10 | Reserves | | | | | Calculated EPS | 0.32 | -2.25 | -6.02 | -2.77 | Calculated EPS (Annualised) | 1.26 | -8.99 | -24.10 | -11.08 | No of Public Share Holdings | 7,864,202.00 | 7,864,202.00 | 7,864,202.00 | 7,864,202.00 | % of Public Share Holdings | 49.68 | 49.68 | 49.68 | 49.68 | | | | | | PBIDTM% (Excl OI) | 7.17 | 2.69 | -3.97 | 0.27 | PBIDTM% | 7.17 | 2.72 | -3.95 | 0.59 | PBDTM% | 3.77 | -1.25 | -7.85 | -3.18 | PBTM% | 0.05 | -5.83 | -11.76 | -6.20 | PATM% | 0.51 | -4.36 | -10.90 | -4.81 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|